Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Net Margin (2016 - 2025)

Vanda Pharmaceuticals' Net Margin history spans 16 years, with the latest figure at 246.81% for Q4 2025.

  • For Q4 2025, Net Margin fell 23757.0% year-over-year to 246.81%; the TTM value through Dec 2025 reached 102.02%, down 9251.0%, while the annual FY2025 figure was 102.02%, 9251.0% down from the prior year.
  • Net Margin for Q4 2025 was 246.81% at Vanda Pharmaceuticals, down from 40.15% in the prior quarter.
  • Across five years, Net Margin topped out at 14.25% in Q2 2021 and bottomed at 246.81% in Q4 2025.
  • The 5-year median for Net Margin is 2.47% (2023), against an average of 18.67%.
  • The largest annual shift saw Net Margin soared 1585bps in 2023 before it tumbled -23757bps in 2025.
  • A 5-year view of Net Margin shows it stood at 10.48% in 2021, then grew by 2bps to 10.68% in 2022, then crashed by -150bps to 5.3% in 2023, then plummeted by -74bps to 9.24% in 2024, then tumbled by -2572bps to 246.81% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Net Margin are 246.81% (Q4 2025), 40.15% (Q3 2025), and 51.73% (Q2 2025).